Array Biopharma Inc.

Genentech, Inc.

Indrani W Gunawardana

James F Blake

Eli M Wallace

Peter J Mohr

Mark Joseph Chicarelli

Michael Lyon

Yvan Le Huerou

Bin Wang

Adam Wade Cook

Li Ren

David A Moreno

Andrew T Metcalf

Kevin W Hunt

Steven Armen Boyd

Kevin Ronald Condroski

Tony P Tang

Thomas Daniel Aicher

Huifen Chen

Lewis J Gazzard

Jacob Bradley Schwarz

Ronald Jay Hinklin

John Peter Fischer

Jay Bradford Fell

Brad Newhouse

Ajay Singh

Allen A Thomas

Timothy M Turner

Jane Schmidt

Steven Wade Andrews

John Joseph Gaudino

Erik James Hicken

Todd T Romoff

Francis X Sullivan

Steve Do

Stephen S Gonzales

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R, R, R, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrrolopyridines as kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed. 

Provided are intermediates having the formulas wherein R, R, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.

Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives

Provided are compounds of Formula (I): wherein R, R, R, L and Dare as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein. 

Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazolopyridines as kinase inhibitors

Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Growing community of inventors

Boulder, CO, United States of America

Indrani W Gunawardana